AI Earnings Predictions for Clarivate Plc (CLVT)

clvt-20260224

0001764046false00-000000000017640462026-02-242026-02-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

February 24, 2026

Date of Report (date of earliest event reported)

CLARIVATE PLC

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

(State or other jurisdiction of incorporation or organization)

001-38911

(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

70 St. Mary Axe

London

EC3A 8BE

United Kingdom

(Address of Principal Executive Offices)

(44) 207-433-4000

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Ordinary Shares, no par valueCLVTNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On February 24, 2026, Clarivate Plc (the “Company”) issued a press release announcing earnings for the fourth quarter ended December 31, 2025. The press release has been furnished with this Form 8-K as Exhibit 99.1 and is posted on the investor relations section of the Company’s website (http://ir.clarivate.com/).

The information in this Item 2.02, including Exhibit 99.1 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 7.01. Regulation FD Disclosure.

On February 24, 2026, the Company posted to its website supplemental information related to revenue, earnings, and guidance. The supplemental information has been furnished with this Current Report on Form 8-K as Exhibit 99.2 and is posted on the investor relations section of the Company’s website (http://ir.clarivate.com/).

The information in this Item 7.01, including Exhibit 99.2 furnished herewith, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any filing pursuant to the Securities Act or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

No.Description

99.1 Press release issued by Clarivate Plc dated February 24, 2026

99.2 Supplemental Information dated February 24, 2026

104 The cover page from the Company's Current Report on Form 8-K dated February 24, 2026, formatted in Inline XBRL

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLARIVATE PLC

Date: February 24, 2026 By: /s/ Jonathan M. Collins

Name: Jonathan M. Collins

Executive Vice President & Chief Financial Officer

EX-99.1

2 ex991q32025earningsrelease.htm

EX-99.1

Document

Clarivate Reports Third Quarter 2025 Results

— Continued acceleration of organic ACV —

— Raises 2025 Revenues Outlook —

— Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter —

London, UK -- October 29, 2025 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2025.

“The third quarter demonstrated continued improved financial and operational performance, underscoring the effectiveness of our Value Creation Plan and the increased focus, growth and innovation it enables. By accelerating product and AI development, investing in proprietary assets, and collaborating closely with our customers, we are optimizing our business model and supporting improved sales execution, which is driving organic ACV growth,” said Matti Shem Tov, Chief Executive Officer. “We remain committed to increasing our core subscription and recurring revenue mix, rationalizing our solutions portfolio, and unlocking greater value for our shareholders. With strong talent, disciplined cost management, and enterprise technology as key enablers, we are well-positioned to deliver sustainable growth and long-term success.”

Total revenues for the third quarter of 2025 were $623.1 million, compared to total revenues of $622.2 million for the third quarter of 2024. Organic revenues for the third quarter of 2025 decreased 0.1%, as organic subscription growth of 1.2%, was offset by lower organic re-occurring and transactional revenues. Organic ACV grew 1.6% compared to September 30, 2024, and the mix of organic recurring revenue to total revenue through nine months of this year has improved 800 bps to 88%, compared to 80% for the prior year ended December 31, 2024.

Net loss for the third quarter of 2025 was $28.3 million, or $0.04 per diluted share, compared to a net loss of $65.6 million, or $0.09 per diluted share, for the third quarter of 2024. Adjusted net income for the third quarter of 2025 was $119.3 million, or $0.18 per diluted share, compared to $134.1 million, or $0.19 per diluted share, for the third quarter of 2024. Adjusted EBITDA for the third quarter of 2025 was $252.4 million, compared to Adjusted EBITDA of $264.4 million for the third quarter of 2024.

Total revenues through nine months of 2025 were $1,838.2 million, compared to total revenues of $1,893.7 million through nine months of 2024, due to inorganic divestitures and disposals. Organic revenues through nine months of 2025 increased 0.2%, due to a 0.6% increase in organic recurring revenues, partially offset by lower organic transactional revenues.

Net loss through nine months of 2025 was $204.2 million, or $0.30 per diluted share, compared to a net loss of $444.9 million, or $0.69 per diluted share, through nine months of 2024. Adjusted net income through nine months of 2025 was $338.4 million, or $0.49 per diluted share, compared to $379.8 million, or $0.52 per diluted share, through nine months of 2024. Adjusted EBITDA through nine months of 2025 was $747.2 million, compared to Adjusted EBITDA of $775.1 million through nine months of 2024.

Clarivate generated $468.6 million of operating cash flow and $276.1 million of free cash flow through nine months of 2025 and used approximately $150 million to repurchase 34.8 million ordinary shares including 11.7 million shares in the third quarter of 2025.

1

Selected Financial Information

(In millions, except percentages and per share data), (unaudited)Three Months Ended September 30,ChangeNine Months Ended September 30,Change

20252024$%20252024$%

Revenues$623.1 $622.2 $0.9 0.1 %$1,838.2 $1,893.7 $(55.5)(2.9)%

Net income (loss)$(28.3)$(65.6)$37.3 56.9 %$(204.2)$(444.9)$240.7 54.1 %

Adjusted net income(1) $119.3 $134.1 $(14.8)(11.0)%$338.4 $379.8 $(41.4)(10.9)%

Adjusted EBITDA(1) $252.4 $264.4 $(12.0)(4.5)%$747.2 $775.1 $(27.9)(3.6)%

Diluted EPS$(0.04)$(0.09)$0.05 55.6 %$(0.30)$(0.69)$0.39 56.5 %

Adjusted diluted EPS(1) $0.18 $0.19 $(0.01)(5.3)%$0.49 $0.52 $(0.03)(5.8)%

Net cash provided by operating activities$181.1 $202.9 $(21.8)(10.7)%$468.6 $505.3 $(36.7)(7.3)%

Free cash flow(1) $115.5 $126.3 $(10.8)(8.6)%$276.1 $298.4 $(22.3)(7.5)%

Third Quarter 2025 Commentary

Subscription revenues decreased $5.7 million, or (1.4)%, to $405.4 million. Organic subscription revenues increased 1.2%, primarily due to new sales and price increases.

Re-occurring revenues decreased $1.4 million, or (1.3)%, to $105.3 million. Organic re-occurring revenues decreased 3.2%, primarily due to lower IP volumes and sales.

Recurring revenues, which consist of subscription and re-occurring revenues, increased 0.3% organically.

Transactional revenues increased $8.0 million, or 7.7%, to $112.4 million, primarily due to higher transactional book sales attributed to A&G wind-down products. Organic transactional rev

EX-99.1

2 ex991q22025earningsrelease.htm

EX-99.1

Document

Clarivate Reports Second Quarter 2025 Results

— Continued acceleration of organic ACV and recurring organic revenue growth —

— Delivered improved organic recurring revenue mix —

— Reaffirmed 2025 Outlook —

— Repurchased 11.5 million ordinary shares in the second quarter —

London, UK -- July 30, 2025 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2025.

Total revenues for the second quarter of 2025 were $621.4 million, compared to total revenues of $650.3 million for the second quarter of 2024, due to inorganic divestitures and disposals. Organic revenues for the second quarter of 2025 increased 0.5%, compared to the second quarter of 2024, due to a 0.8% increase in organic recurring revenues, partially offset by lower organic transactional revenues. Organic ACV grew 1.3% compared to June 30, 2024, and the mix of organic recurring revenue to total revenue for the first half of this year is now at 88%, an improvement of 800 bps compared to 80% for the prior year ended December 31, 2024.

Net loss for the second quarter of 2025 was $72.0 million, or $0.11 per diluted share, compared to a net loss of $304.3 million, or $0.46 per diluted share, for the second quarter of 2024. Adjusted net income for the second quarter of 2025 was $123.3 million, or $0.18 per diluted share, compared to $142.2 million, or $0.20 per diluted share, for the second quarter of 2024. Adjusted EBITDA for the second quarter of 2025 was $261.6 million, compared to Adjusted EBITDA of $274.4 million for the second quarter of 2024.

Total revenues for the first half of 2025 were $1,215.1 million, compared to total revenues of $1,271.5 million for the first half of 2024, due to inorganic divestitures and disposals. Organic revenues for the first half of 2025 increased 0.4%, compared to the first half of 2024, due to a 0.7% increase in organic recurring revenues, partially offset by lower organic transactional revenues.

Net loss for the first half of 2025 was $175.9 million, or $0.26 per diluted share, compared to a net loss of $379.3 million, or $0.61 per diluted share, for the first half of 2024. Adjusted net income for the first half of 2025 was $219.1 million, or $0.32 per diluted share, compared to $245.7 million, or $0.34 per diluted share, for the first half of 2024. Adjusted EBITDA for the first half of 2025 was $494.8 million, compared to Adjusted EBITDA of $510.7 million for the first half of 2024.

Clarivate generated $287.5 million of operating cash flow and $160.6 million of free cash flow in the first half of 2025 and used approximately $100 million to repurchase 23.2 million ordinary shares at an average price of $4.29 per share.

“We reported solid second quarter performance and delivered growth in our key metrics. We have good momentum underway building off a solid first half of the year,” said Matti Shem Tov, Chief Executive Officer. “There are early indications that our Value Creation Plan is driving improved performance and I’m pleased by the way in which the team is coming together to move the business forward.”

“Looking ahead, we believe that the enhancements we made to the sales operating model to improve execution, customer engagement, and retention, as well as AI tailwinds benefiting our IP business, will support Clarivate’s profitability and value creation.”

1

Selected Financial Information

(In millions, except percentages and per share data), (unaudited) Three Months Ended June 30,ChangeSix Months Ended June 30,Change

20252024$%20252024$%

Revenues$621.4 $650.3 $(28.9)(4.4)%$1,215.1 $1,271.5 $(56.4)(4.4)%

Net income (loss) $(72.0)$(304.3)$232.3 76.3%$(175.9)$(379.3)$203.4 53.6%

Adjusted net income(1) $123.3 $142.2 $(18.9)(13.3)%$219.1 $245.7 $(26.6)(10.8)%

Adjusted EBITDA(1) $261.6 $274.4 $(12.8)(4.7)%$494.8 $510.7 $(15.9)(3.1)%

Diluted EPS $(0.11)$(0.46)$0.35 76.1%$(0.26)$(0.61)$0.35 57.4%

Adjusted diluted EPS(1) $0.18 $0.20 $(0.02)(10.0)%$0.32 $0.34 $(0.02)(5.9)%

Net cash provided by operating activities $116.3 $126.2 $(9.9)(7.8)%$287.5 $302.4 $(14.9)(4.9)%

Free cash flow(1) $50.3 $60.3 $(10.0)(16.6)%$160.6 $172.1 $(11.5)(6.7)%

Second Quarter 2025 Commentary

Subscription revenues of $405.7 million were essentially flat. Organic subscription revenues increased 1.7%, primarily due to new sales and price increases.

Re-occurring revenues increased $0.3 million, or 0.3%, to $108.9 million. Organic re-occurring revenues decreased 2.3%, primarily due to timing of IP patent renewal volumes, as organic re-occurring revenues increased 1.4% for the first half of 2025.

Recurring revenues, which consist of subscription and re-occurring revenues, increased 0.8% organically.

Transactional revenues decreased $29.3 million, or 21.5%, to $106.8 million, primarily due to product group wind-downs within A&G. Organic transacti

EX-99.1

2 ex991q12025earningsrelease.htm

EX-99.1

Document

Clarivate Reports First Quarter 2025 Results

— Accelerated recurring organic revenue growth —

— Reaffirmed 2025 Outlook —

— Repurchased $50 million ordinary shares —

London, UK -- April 29, 2025 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2025.

Total revenues for the first quarter of 2025 was $593.7 million, compared to total revenues of $621.2 million for the first quarter of 2024. Organic revenues for the first quarter of 2025 increased 0.3%, compared to the first quarter of 2024, due to a 0.6% increase in organic recurring revenues, partially offset by lower organic transactional revenues.

Net loss for the first quarter of 2025 was $103.9 million, or $0.15 per diluted share, compared to a net loss of $75.0 million, or $0.14 per diluted share, for the first quarter of 2024. Adjusted net income for the first quarter of 2025 was $95.8 million, or $0.14 per diluted share, compared to $103.5 million, or $0.14 per diluted share, for the first quarter of 2024. Adjusted EBITDA for the first quarter of 2025 was $233.2 million, compared to Adjusted EBITDA of $236.3 million for the first quarter of 2024.

Clarivate generated $171.2 million of operating cash flow and $110.3 million of free cash flow in the first quarter of 2025 and repurchased $50.0 million of ordinary shares.

“We delivered improved sequential organic ACV growth in the first quarter from higher renewals and new business wins, reinforcing the impact of our Value Creation Plan” said Matti Shem Tov, Chief Executive Officer. “Clarivate’s offerings are mission-critical for our users and competitively advantaged, enabling us to successfully transition to a subscription-first strategy, improve renewal rates, and drive higher usage in key products where we have invested. Our Value Creation Plan is on track despite the volatile macro environment as we continue to effectively execute our long-term growth strategy.”

1

Selected Financial Information

Three Months Ended March 31,Change

(In millions, except percentages and per share data), (unaudited) 20252024$%

Revenues$593.7 $621.2 $(27.5)(4.4)%

Net income (loss) $(103.9)$(75.0)$(28.9)(38.5)%

Adjusted net income(1) $95.8 $103.5 $(7.7)(7.4)%

Adjusted EBITDA(1) $233.2 $236.3 $(3.1)(1.3)%

Diluted EPS $(0.15)$(0.14)$(0.01)(7.1)%

Adjusted diluted EPS(1) $0.14 $0.14 $— —%

Net cash provided by operating activities $171.2 $176.2 $(5.0)(2.8)%

Free cash flow(1) $110.3 $111.8 $(1.5)(1.3)%

First Quarter 2025 Commentary

Total revenues decreased $27.5 million, or 4.4%, to $593.7 million, primarily due to inorganic divestitures, disposals, and foreign currency translation impacts. Organic revenues increased 0.3%.

Subscription revenues decreased $14.5 million, or 3.6%, to $388.6 million, primarily due to the ScholarOne product group divestiture. Organic subscription revenues decreased 0.6%.

Re-occurring revenues increased $3.4 million, or 3.3%, to $105.9 million. Organic re-occurring revenues increased 5.3%, primarily due to higher IP patent renewal volumes.

Recurring revenues, which consist of subscription and re-occurring revenues, increased 0.6% organically.

Transactional revenues decreased $16.4 million, or 14.2%, to $99.2 million, primarily due to the Valipat product group divestiture and product group wind-downs within A&G. Organic transactional revenues decreased 2.3%.

Balance Sheet and Cash Flow

As of March 31, 2025, cash and cash equivalents of $354.0 million increased $58.8 million compared to December 31, 2024.

The Company's total debt outstanding was $4,570.8 million as of March 31, 2025, largely unchanged compared to December 31, 2024.

Net cash provided by operating activities of $171.2 million for the three months ended March 31, 2025 decreased $5.0 million compared to the prior year period, primarily due to an increase in restructuring costs. Free cash flow for the three months ended March 31, 2025 was $110.3 million, a decrease of $1.5 million compared to the prior year period.

2

Reaffirms Outlook for 2025 (forward-looking statement)

“The business returned to modest organic growth in the first quarter, and Adjusted EBITDA margin accelerated by 130 basis points,” said Jonathan Collins, Executive Vice President and Chief Financial Officer. “We generated strong free cash flow of over $110 million, enabling us to repurchase $50 million of our shares, consistent with our capital allocation strategy to return value to shareholders. Given the solid performance in the first quarter, we are reaffirming our full year 2025 outlook.”

The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.

2025 Outlook

Organic ACV 1.0% to 2.0%

Recurring Organic Revenue Growth (1.0)% to 1.0%

Revenues $2.28B to $2.40B

Adjusted EBITDA(1)

$940M to $1.00B

Adjusted

EX-99.1

2 ex991q42024earningsrelease.htm

EX-99.1

Document

Clarivate Reports Fourth Quarter and Full Year 2024 Results

— Accelerates transition from transactional to subscription and re-occurring revenue —

— Launches new product innovation for Academia & Government and Life Sciences & Healthcare —

— Repurchased $200 million ordinary shares and pre-paid $198 million of debt in 2024 as part of balanced capital allocation strategy —

— Initiates review of strategic alternatives including potential divestitures —

— Provides 2025 Outlook —

London, UK -- February 19, 2025 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2024.

Total revenue for the fourth quarter of 2024 was $663.0 million, compared to total revenue of $683.7 million in the fourth quarter of 2023. Organic revenues for the fourth quarter of 2024 decreased 0.7%, as an increase in subscription and transactional revenues was offset by lower re-occurring revenues, compared to the fourth quarter of 2023.

Net loss for the fourth quarter of 2024 was $191.8 million, or $0.27 per diluted share, an improvement compared to a net loss of $843.9 million, or $1.30 per diluted share, in the fourth quarter of 2023. Adjusted net income for the fourth quarter of 2024 was $145.5 million, or $0.21 per diluted share, compared to $163.4 million, or $0.23 per diluted share, for the fourth quarter of 2023. Adjusted EBITDA was $285.3 million for the fourth quarter of 2024, compared to Adjusted EBITDA of $298.2 million for the fourth quarter of 2023.

Total revenue for the full year of 2024 was $2.56 billion, compared to total revenue of $2.63 billion for the full year of 2023. Organic revenues decreased 1.4%, as an increase in subscription revenues was offset by lower transactional and re-occurring revenues.

Net loss for the full year of 2024 was $636.7 million, or $0.96 per diluted share, an improvement compared to a net loss of $911.2 million, or $1.47 per diluted share, for the full year of 2023. Adjusted net income for the full year of 2024 was $525.3 million, or $0.73 per diluted share, compared to $599.1 million, or $0.82 per diluted share, for the full year of 2023. Adjusted EBITDA was $1,060.4 million for the full year of 2024, compared to Adjusted EBITDA of $1,117.2 million for the full year of 2023.

Clarivate generated $357.5 million of free cash flow for the full year of 2024 and repurchased $200.0 million of ordinary shares and pre-paid $198.1 million of term-loan debt. In December 2024, the Board of Directors authorized a new share repurchase program of up to $500.0 million of the Company’s outstanding ordinary shares through open-market purchases for a period of two years, from January 1, 2025 through December 31, 2026.

“We are committed to reinvigorating our business to deliver healthy organic growth and build for the future,” said Matti Shem Tov, Chief Executive Officer. “Last year we released a string of AI-powered product enhancements, and as part of our Value Creation Plan (VCP), we recently launched new subscription-based solutions including ProQuest e-Books, ProQuest Digital Collections and DRG Fusion. We are focused on driving subscription and re-occurring revenue growth and plan to discontinue sales of certain low-margin transactional products in 2025 and 2026, which will improve our revenue predictability.”

Mr. Shem Tov continued: “Under our VCP initiatives, we are improving our sales execution by enhancing key leadership roles, realigning account management models around specialist areas, and investing in customer success teams. We are harnessing the power of technology and AI to accelerate product innovation and drive development velocity through customer collaboration. We believe the steps we are taking will improve our financial performance and operational efficiency.”

1

Selected Financial Information

Three Months Ended December 31,Change Year Ended

December 31, Change

(in millions, except percentages and per share data), (unaudited)20242023$%20242023$%

Revenues$663.0 $683.7 $(20.7)(3.0)%$2,556.7 $2,628.8 $(72.1)(2.7)%

Net income (loss)$(191.8)$(843.9)$652.1 77.3 %$(636.7)$(911.2)$274.5 30.1 %

Adjusted net income(1) $145.5 $163.4 $(17.9)(11.0)%$525.3 $599.1 $(73.8)(12.3)%

Adjusted EBITDA(1) $285.3 $298.2 $(12.9)(4.3)%$1,060.4 $1,117.2 $(56.8)(5.1)%

Diluted EPS$(0.27)$(1.30)$1.03 79.2 %$(0.96)$(1.47)$0.51 34.7 %

Adjusted diluted EPS(1) $0.21 $0.23 $(0.02)(8.7)%$0.73 $0.82 $(0.09)(11.0)%

Net cash provided by operating activities$141.3 $190.9 $(49.6)(26.0)%$646.6 $744.2 $(97.6)(13.1)%

Free cash flow(1) $59.1 $127.0 $(67.9)(53.5)%$357.5 $501.7 $(144.2)(28.7)%

Fourth Quarter 2024 Commentary

Revenues for the fourth quarter decreased $20.7 million, or 3.0%, to $663.0 million, primarily due to IP and A&G product group divestitures completed in 2024. Organic revenues decreased $5.0 m

EX-99.1

2 ex991q32024earningsrelease.htm

EX-99.1

Document

Clarivate Reports Third Quarter 2024 Results

London, UK -- November 6, 2024 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

•Revenues of $622.2 million decreased 3.9%

•Organic revenues decreased 2.6%, as an increase in subscription revenues of 0.6% was offset by a decrease in re-occurring revenues of 1.1% and transactional and other revenues of 13.6%

•Net loss of $65.6 million; Net loss per diluted share of $0.09

•Adjusted net income(1) of $134.1 million decreased 12.1%; Adjusted diluted EPS(1) of $0.19 decreased 9.5% or $0.02

•Adjusted EBITDA(1) of $264.4 million decreased 6.0%; Adjusted EBITDA margin(1) of 42.5% decreased 100 basis points primarily due to lower revenues

•Net cash provided by operating activities of $202.9 million increased $39.5 million; Free cash flow(1) of $126.3 million increased $24.6 million primarily due to the timing of working capital

Nine Months Ended September 30, 2024 Financial Highlights

•Revenues of $1,893.7 million decreased 2.6%

•Organic revenues decreased 1.5% as an increase in subscription revenues of 1.2% was offset by a decline in re-occurring revenues of 2.3% and transactional and other revenues of 9.3%

•Net loss of $444.9 million; Net loss per diluted share of $0.69

•Adjusted net income(1) of $379.8 million decreased 12.8%; Adjusted diluted EPS(1) of $0.52 decreased 11.9% or $0.07

•Adjusted EBITDA(1) of $775.1 million decreased 5.4%; Adjusted EBITDA margin(1) of 40.9% decreased 120 basis points primarily due to lower revenues

•Net cash provided by operating activities decreased $48.0 million to $505.3 million; Free cash flow(1) decreased $76.3 million to $298.4 million primarily due to lower operating income and increased capital expenditures

“Clarivate’s third quarter results are unsatisfactory and reflect an overdependency on fluctuating transactional revenue and areas of the business with low margin characteristics,” said Matti Shem Tov, Chief Executive Officer. “As we look ahead, it is clear the Company has work to do to improve performance. Our Value Creation Plan is designed to increase subscription and re-occurring revenue, improve sales execution, accelerate innovation and continue portfolio solutions rationalization. We will leverage Clarivate’s strong foundation, unique product offerings and talented team to take the necessary actions to improve predictability and drive profitable growth. Alongside the management team and Board, I am invigorated by the opportunities before us and remain focused on successfully executing our strategy to realize Clarivate’s potential.”

Removal of Outlook

As a result of the recent CEO transition and the work being done under the Value Creation Plan, the Company has removed its forward-looking outlook for 2024. All previous outlooks provided by the Company should no longer be relied upon.

1

Selected Financial Information

Three Months Ended September 30,ChangeNine Months Ended September 30,Change

(in millions, except percentages and per share data), (unaudited)20242023 $%20242023$%

Revenues$622.2 $647.2 $(25.0)(3.9)%$1,893.7 $1,945.1 $(51.4)(2.6)%

Net income (loss)$(65.6)$12.3 $(77.9)N/M$(444.9)$(67.3)$(377.6)N/M

Diluted EPS

$(0.09)$(0.01)$(0.08)N/M$(0.69)$(0.18)$(0.51)N/M

Weighted average ordinary shares, diluted 718.7 670.9 47.8 7.1 %690.5 673.9 16.6 2.5 %

Adjusted EBITDA(1) $264.4 $281.4 $(17.0)(6.0)%$775.1 $819.0 $(43.9)(5.4)%

Adjusted net income(1) $134.1 $152.6 $(18.5)(12.1)%$379.8 $435.7 $(55.9)(12.8)%

Adjusted diluted EPS(1) $0.19 $0.21 $(0.02)(9.5)%$0.52 $0.59 $(0.07)(11.9)%

Adjusted weighted average ordinary shares, diluted(1) 723.5 731.4 (7.9)(1.1)%726.1 733.6 (7.5)(1.0)%

Net cash provided by operating activities$202.9 $163.4 $39.5 24.2 %$505.3 $553.3 $(48.0)(8.7)%

Free cash flow(1) $126.3 $101.7 $24.6 24.2 %$298.4 $374.7 $(76.3)(20.4)%

Third Quarter 2024 Commentary

Revenues for the third quarter decreased $25.0 million, or 3.9%, to $622.2 million, primarily due to the divestiture of Valipat in April 2024 and lower transactional sales across all three segments. Organic revenues decreased $16.5 million or 2.6%.

Subscription revenues for the third quarter increased $3.0 million, or 0.7%, to $411.1 million. Organic subscription revenues increased 0.6%, driven by price increases, partially offset by lower net volume in IP and LS&H.

Re-occurring revenues for the third quarter decreased $0.1 million, or 0.1%, to $106.7 million. Organic re-occurring revenues decreased 1.1%, primarily due to lower IP patent renewal volume.

Transactional and other revenues for the third quarter decreased $27.9 million, or 21.1%, to $104.4 million. Organic transactional and other revenues decreased 13.6%, due to lower sales across all three segments.

Balance Sheet and Cash

EX-99.1

2 ex991q22024earningsrelease.htm

EX-99.1

Document

Clarivate Reports Second Quarter 2024 Results

— Reaffirms 2024 Outlook —

London, UK -- August 6, 2024 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

•Revenues of $650.3 million decreased 2.8%

•Organic revenues decreased 0.6%, as an increase in subscription revenues of 0.7% was offset by a decrease in re-occurring revenues of 0.7% and transactional and other revenues of 4.1%

•Net loss of $304.3 million; Net loss per diluted share of $0.46

•Adjusted net income(1) of $142.2 million decreased 6.6%; Adjusted diluted EPS(1) of $0.20 decreased 4.8% or $0.01

•Adjusted EBITDA(1) of $274.4 million decreased 3.7%; Adjusted EBITDA margin(1) of 42.2% decreased 40 basis points primarily due to lower revenues

•Net cash provided by operating activities of $126.2 million decreased $36.2 million; Free cash flow(1) of $60.3 million decreased $44.5 million primarily due to the timing of working capital

Six Months Ended June 30, 2024 Financial Highlights

•Revenues of $1,271.5 million decreased 2.0%

•Organic revenues decreased 1.1% as an increase in subscription revenues of 1.5% was offset by a decline in re-occurring revenues of 2.9% and transactional and other revenues of 7.3%

•Net loss of $379.3 million; Net loss per diluted share of $0.61

•Adjusted net income(1) of $245.7 million decreased 13.2%; Adjusted diluted EPS(1) of $0.34 decreased 12.8% or $0.05

•Adjusted EBITDA(1) of $510.7 million decreased 5.0%; Adjusted EBITDA margin(1) of 40.2% decreased 120 basis points primarily due to lower revenues

•Net cash provided by operating activities decreased $87.5 million to $302.4 million; Free cash flow(1) decreased $100.9 million to $172.1 million primarily due to lower operating income and increased capital expenditures

“We continue to invest in innovation and make progress on our strategy of returning to growth. During the last quarter, we launched several new, next-generation product offerings across all three segments such as the Research Horizon NavigatorTM, Trademark Watch Analyzer, and Epidemiology Intelligence,” said Jonathan Gear, Chief Executive Officer. “We are seeing our customers respond positively to our operational and product improvements, and as a result improved renewal rates and new customer wins, which will drive a return to organic growth in the second half of this year.”

1

Selected Financial Information

Three Months Ended June 30,ChangeSix Months Ended June 30,Change

(in millions, except percentages and per share data), (unaudited)20242023 $%20242023$%

Revenues$650.3 $668.8 $(18.5)(2.8)%$1,271.5 $1,297.9 $(26.4)(2.0)%

Net income (loss)$(304.3)$(123.1)$(181.2)N/M$(379.3)$(79.6)$(299.7)N/M

Diluted EPS

$(0.46)$(0.21)$(0.25)N/M$(0.61)$(0.17)$(0.44)N/M

Weighted average ordinary shares, diluted 685.6 675.9 9.7 1.4 %676.2 675.4 0.8 0.1 %

Adjusted EBITDA(1) $274.4 $284.9 $(10.5)(3.7)%$510.7 $537.6 $(26.9)(5.0)%

Adjusted net income(1) $142.2 $152.2 $(10.0)(6.6)%$245.7 $283.1 $(37.4)(13.2)%

Adjusted diluted EPS(1)(2) $0.20 $0.21 $(0.01)(4.8)%$0.34 $0.39 $(0.05)(12.8)%

Adjusted weighted average ordinary shares, diluted(1) 726.8 734.9 (8.1)(1.1)%727.2 734.8 (7.6)(1.0)%

Net cash provided by operating activities$126.2 $162.4 $(36.2)(22.3)%$302.4 $389.9 $(87.5)(22.4)%

Free cash flow(1) $60.3 $104.8 $(44.5)(42.5)%$172.1 $273.0 $(100.9)(37.0)%

Second Quarter 2024 Commentary

Revenues for the second quarter decreased $18.5 million, or 2.8%, to $650.3 million, primarily due to the divestiture of Valipat in April 2024 and the negative impact of foreign exchange as a result of the strengthening of the U.S. dollar. Organic revenues decreased $3.9 million or 0.6%.

Subscription revenues for the second quarter decreased $0.4 million, or 0.1%, to $405.6 million. Organic subscription revenues increased 0.7%, driven by price increases.

Re-occurring revenues for the second quarter decreased $2.4 million, or 2.2%, to $108.6 million. Organic re-occurring revenues decreased 0.7%, primarily due to lower IP patent renewal volumes.

Transactional and other revenues for the second quarter decreased $15.7 million, or 10.3%, to $136.1 million. Organic transactional and other revenues decreased 4.1%, due to lower sales across all three segments.

Balance Sheet and Cash Flow

As of June 30, 2024, cash and cash equivalents of $376.4 million increased $5.7 million compared to December 31, 2023.

The Company's total debt outstanding as of June 30, 2024 was $4,717.2 million, a decrease of $53.1 million compared to December 31, 2023, driven by an accelerated debt repayment.

Net cash provided by operating activities of $302.4 million for the six months ended June 30, 2024 decreased $87.5 million compared to the prior year period, primarily due to timing differences in working capital.

EX-99.1

2 ex991q12024earningsrelease.htm

EX-99.1

Document

Clarivate Reports First Quarter 2024 Results

— Reaffirms 2024 Outlook —

London, UK -- May 8, 2024 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2024.

First Quarter 2024 Financial Highlights

•Revenues of $621.2 million decreased 1.3%

•Organic revenues decreased 1.7%, as an increase in subscription revenues of 2.4% was more than offset by a decrease in transactional and other revenues of 11.4% and re-occurring revenues of 5.1%

•Net loss attributable to ordinary shares of $93.8 million; Net loss per diluted share of $0.14

•Adjusted net income(1) of $103.5 million decreased 20.9%; Adjusted diluted EPS(1) of $0.14 decreased 22.2% or $0.04

•Adjusted EBITDA(1) of $236.3 million decreased 6.5%; Adjusted EBITDA margin(1) of 38.0% decreased 220 basis points primarily due to lower revenues

•Net cash provided by operating activities of $176.2 million decreased $51.3 million; Free cash flow(1) of $111.8 million decreased $56.4 million primarily due to the timing of working capital

“We are making great progress this year on key objectives including product investments and operational initiatives to drive future organic revenue growth,” said Jonathan Gear, Chief Executive Officer. “Our Intellectual Property segment refined its go-to-market operating model and revived patent intelligence solutions, which is resulting in commercial success across our software solutions, particularly IPFolio, and improved Derwent renewal rates. We released a new real-world data framework in the Life Sciences & Healthcare segment and were awarded deals with two top-10 global pharmaceutical clients. Additionally, we recently acquired two startup companies, MotionHall and Global QMS, Inc. which will enhance our portfolio and expertise in the LS&H segment. We continue to make the necessary improvements to revitalize Clarivate and drive enhanced value for clients, colleagues, and shareholders.”

1

Selected Financial Information

Three Months Ended March 31,Change

(In millions, except percentages and per share data), (unaudited) 20242023$%

Revenues$621.2 $629.1 $(7.9)(1.3)%

Net income (loss) attributable to ordinary shares$(93.8)$24.7 $(118.5)N/M

Net income (loss) per share, diluted$(0.14)$0.04 $(0.18)N/M

Weighted-average ordinary shares (diluted)666.9 679.3 (12.4)(1.8)%

Adjusted EBITDA(1) $236.3 $252.7 $(16.4)(6.5)%

Adjusted net income(1) $103.5 $130.9 $(27.4)(20.9)%

Adjusted diluted EPS(1)(2) $0.14 $0.18 $(0.04)(22.2)%

Adjusted weighted-average ordinary shares (diluted)(1)

727.6 734.7 (7.0)(1.0)%

Net cash provided by operating activities $176.2 $227.5 $(51.3)(22.5)%

Free cash flow(1) $111.8 $168.2 $(56.4)(33.5)%

First Quarter 2024 Commentary

Revenues for the first quarter decreased $7.9 million, or 1.3%, to $621.2 million. Organic revenues decreased $10.5 million or 1.7%.

Subscription revenues for the first quarter increased $9.9 million, or 2.5%, to $403.1 million. Organic subscription revenues increased 2.4%, driven by price increases.

Re-occurring revenues for the first quarter decreased $5.2 million, or 4.8%, to $102.5 million. Organic re-occurring revenues decreased 5.1%, primarily due to lower IP patent renewal volumes.

Transactional and other revenues for the first quarter decreased $12.6 million, or 9.8%, to $115.6 million. Organic transactional and other revenues decreased 11.4%, due to lower A&G volumes and LS&H real world data sales.

Balance Sheet and Cash Flow

As of March 31, 2024, cash and cash equivalents of $361.8 million decreased $8.9 million compared to December 31, 2023.

The Company's total debt outstanding as of March 31, 2024 was $4,722.6 million, a decrease of $47.7 million compared to December 31, 2023, driven by an accelerated debt repayment.

Net cash provided by operating activities of $176.2 million for the three months ended March 31, 2024 decreased $51.3 million compared to $227.5 million for the prior year period, primarily due to timing differences in working capital. Free cash flow(1) for the three months ended March 31, 2024, was $111.8 million, a decrease of $56.4 million compared to the prior year period.

2

Reaffirmed Outlook for 2024 (forward-looking statement)

“With first quarter results in line with our expectations, we reaffirm our 2024 full year outlook,” said Jonathan Collins, Executive Vice President and Chief Financial Officer. “Currently, we anticipate a sequential improvement in organic revenue growth in the second quarter compared to the first quarter. For the full year, we continue to expect to deliver improved growth across our three segments driven by the benefit of product investments and modestly improving market conditions.”

The full year outlook presented below assumes no further acquisitions, divestitures, or unanticipated events.

2024 Outlook

Revenues $2.57B to $2.67B

EX-99.1

2 ex991q42023earningsrelease.htm

EX-99.1

Document

Clarivate Reports Fourth Quarter and Full Year 2023 Results

— Provides 2024 Outlook —

London, UK -- February 27, 2024 Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a leading global provider of transformative intelligence, today reported results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights

•Revenues of $683.7 million increased 1.2%, and decreased 0.6% at constant currency(2)

•Organic revenues increased 0.1% as increases in subscription revenues of 2.6% and re-occurring revenues of 3.8% were offset by a decline in transactional and other revenues of 8.3%

•Net loss attributable to ordinary shares of $863.0 million due to the $844.7 non-cash impairment of goodwill and intangible assets; Net loss per diluted share of $1.30

•Adjusted net income(1) of $163.4 million decreased 0.4%; Adjusted diluted EPS(1) of $0.23 increased 4.5% or $0.01

•Adjusted EBITDA(1) of $298.2 million decreased 2.0%; Adjusted EBITDA Margin(1) of 43.6% decreased 150 basis points

•Net cash provided by operating activities increased $54.0 million to $190.9 million; Free cash flow(1) increased $36.5 million to $127.0 million

Full Year 2023 Financial Highlights

•Revenues of $2,628.8 million decreased 1.2%, and 2.1% at constant currency(2), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period

•Organic revenues increased 0.3% as increases in subscription revenues of 2.4% and re-occurring revenues of 0.2% were offset by a decline in transactional and other revenues of 5.4%

•Net loss attributable to ordinary shares of $986.6 million improved from a loss of $4,035.6 million for the full year 2022 due to a $3,469.2 million reduction of non-cash impairment charges of goodwill and intangible assets; Net loss per diluted share of $1.47 improved by $4.77

•Adjusted net income(1) of $599.1 million decreased 4.6%; Adjusted diluted EPS(1) of $0.82 decreased 3.5% or $0.03

•Adjusted EBITDA(1) of $1,117.2 million increased 0.4% and Adjusted EBITDA Margin(1) of 42.5% increased 70 basis points

•Net cash provided by operating activities increased $234.9 million to $744.2 million; Free cash flow(1) increased $195.3 million to $501.7 million

“In 2023, we delivered subscription revenue growth and navigated through market headwinds. We achieved cost synergy targets and generated significant cash flow, which allowed us to increase the pay down of debt and repurchase ordinary shares,” said Jonathan Gear, Chief Executive Officer. “With organic revenue growth below our expectations, we launched a multi-year transformation plan to return to market growth rates. The plan outlines how we will continue to make strategic investments to accelerate new product development and strengthen our focus by divesting non-core assets. I am confident we are making the right investments that, when combined with our extensive content, solutions and artificial intelligence capabilities, will drive organic growth and create shareholder value.”

1

Selected Financial Information

The prior year results include MarkMonitor, which was divested on October 31, 2022, for which there are no comparable amounts in the current year periods.

Three Months Ended December 31,ChangeYear Ended December 31,Change

(in millions, except percentages and per share data), (unaudited)20232022 $%20232022$%

Revenues, net$683.7 $675.3 $8.4 1.2 %$2,628.8 $2,659.8 $(31.0)(1.2)%

Net income (loss) attributable to ordinary shares$(863.0)$304.3 $(1,167.3)N/M$(986.6)$(4,035.6)$3,049.0 N/M

Net income (loss) per share, diluted$(1.30)$0.44 $(1.74)N/M$(1.47)$(6.24)$4.77 N/M

Weighted-average ordinary shares (diluted)665.0 731.0 (66.0)(9.0)%671.6 678.6 (7.0)(1.0)%

Adjusted EBITDA(1) $298.2 $304.4 $(6.2)(2.0)%$1,117.2 $1,112.7 $4.5 0.4 %

Adjusted net income(1) $163.4 $164.0 $(0.6)(0.4)%$599.1 $628.0 $(28.9)(4.6)%

Adjusted diluted EPS(1)(3) $0.23 $0.22 $0.01 4.5 %$0.82 $0.85 $(0.03)(3.5)%

Adjusted weighted-average ordinary shares (diluted)(1)

724.4 731.2 (6.8)(0.9)%731.3 737.1 (5.8)(0.8)%

Net cash provided by operating activities $190.9 $136.9 $54.0 39.4 %$744.2 $509.3 $234.9 46.1 %

Free cash flow(1) $127.0 $90.5 $36.5 40.3 %$501.7 $306.4 $195.3 63.7 %

Fourth Quarter 2023 Commentary

Revenues for the fourth quarter increased $8.4 million, or 1.2%, to $683.7 million, and decreased 0.6% on a constant currency basis(2). Organic revenues increased $1.0 million or 0.1%.

Subscription revenues for the fourth quarter increased $11.8 million, or 3.0%, to $410.8 million, and increased 1.1% on a constant currency basis(2). Organic subscription revenues increased 2.6%, driven by growth across all three product segments: Academia & Government (A&G), Intellectual Property (IP) and Life Sciences & Healthcare (LS&H).

Re-occurring revenues for the fourth quarter increased $6.4 million, or 5.7% to $119.1 mill

EX-99.1

2 tm243777d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

Clarivate Announces Commencement of Term Loan Refinancing Transaction

London, U.K., January 22, 2024 – Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced today the launch of a process to refinance the Company’s 2026 Term Loan B credit facility that would extend the maturity to 2031 for a new combined term loan amount of $2.2 billion.

“We are proactively capitalizing on the favorable debt market environment in order to provide further flexibility within our capital structure,” said Jonathan Collins, Executive Vice President and Chief Financial Officer. “With our strong free cash flow, we continue to focus on investing for growth and reducing our debt to drive long-term shareholder value.”

The Company also announced that it expects to record a non-cash goodwill impairment charge in the range of approximately $800 million to $900 million in the fourth quarter 2023, across the Intellectual Property and Life Sciences & Healthcare segments. The charge is expected to lower the Company’s 2023 forecast of a GAAP net loss but will have no impact on the 2023 full year outlook for Revenues, Organic Revenue Growth, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS and Free Cash Flow as outlined in its third quarter 2023 earnings press release issued on November 7, 2023.

Terms of the potential refinancing will be disclosed upon the completion of the transaction. The proposed refinancing is subject to market and other conditions, and there can be no assurance that it will be completed on favorable terms or at all.

About Clarivate

Clarivate™ is a leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

Use of Non-GAAP Financial Measures

Non-GAAP results are not presentations made in accordance with U.S.

generally accepted accounting principles ("GAAP") and are presented only as a supplement to our financial statements based on GAAP. Non-GAAP financial information is provided to enhance the reader’s understanding of our financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP. They are not measures of financial condition or liquidity, and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. As a result, you should not consider such measures in isolation from, or as a substitute for, financial measures or results of operations calculated or determined in accordance with GAAP.

We use non-GAAP measures in our operational and financial

decision-making. We believe that such measures allow us to focus on what we deem to be a more reliable indicator of ongoing operating performance and our ability to generate cash flow from operations, and we also believe that investors may find these non-GAAP financial measures useful for the same reasons. Non-GAAP measures are frequently used by securities analysts, investors, and other interested parties in their evaluation of companies comparable to us, many of which present non-GAAP measures when reporting their results. These measures can be useful in evaluating our performance against our peer companies because we believe the measures provide users with valuable insight into key components of GAAP financial disclosures. However, non-GAAP measures have limitations as analytical tools and because not all companies use identical calculations, our presentation of non-GAAP financial measures may not be comparable to other similarly titled measures of other companies.

Definitions and reconciliations of non-GAAP measures, such as Adjusted

EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Diluted EPS, Free Cash Flow and Standalone Adjusted EBITDA to the most directly comparable GAAP measures are provided within the schedules attached to this release. Our presentation of non-GAAP measures should not be construed as an inference that our future results will be unaffected by any of the adjusted items, or that any projections and estimates will be realized in their entirety or at all.

Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “antic

EX-99.1

2 ex991q32023earningsrelease.htm

EX-99.1

Document

Clarivate Reports Third Quarter 2023 Results

— Reaffirms 2023 Outlook —

London, UK -- November 7, 2023 Clarivate Plc - (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today reported results for the third quarter.

Third Quarter 2023 Financial Highlights

•Revenues of $647.2 million increased 1.8%, and decreased 1.3% at constant currency(2)

•Organic revenues increased 1.7% driven by an increase in transactional and other revenues of 3.5%, subscription revenues of 1.3% and re-occurring revenues of 0.5%

•Net loss attributable to ordinary shares of $6.6 million; Net loss per diluted share of $0.01

•Adjusted Net Income(1) of $152.6 million increased 6.2%; Adjusted Income per diluted share(1) of $0.21 increased 5.0% or $0.01

•Adjusted EBITDA(1) of $281.4 million increased 3.6% driven by cost savings from integration programs; Adjusted EBITDA Margin(1) of 43.5% increased 80 basis points

•Net cash provided by operating activities decreased $44.4 million to $163.4 million; Free cash flow(1) decreased $38.7 million to $101.7 million, driven by timing-related, in quarter working capital requirements

Nine Months Ended September 30, 2023 Financial Highlights

•Revenues of $1,945.1 million decreased 2.0%, and 2.6% at constant currency(2), driven primarily by the divestiture of MarkMonitor in October 2022, for which there were no comparable amounts in the current year period

•Organic revenues increased 0.3% as an increase in subscription revenues of 2.3% was offset by a decline in re-occurring revenues of 1.0% and transactional and other revenues of 4.3%

•Net loss attributable to ordinary shares of $123.6 million; Net loss per diluted share of $0.18

•Adjusted Net Income(1) of $435.7 million decreased 6.1%; Adjusted Income per diluted share(1) of $0.59 decreased 6.3% or $0.04

•Adjusted EBITDA(1) of $819.0 million increased 1.3% driven by cost savings from integration programs; Adjusted EBITDA Margin(1) of 42.1% increased 140 basis points

•Net cash provided by operating activities increased $180.9 million to $553.3 million; Free cash flow(1) increased $158.8 million to $374.7 million

“Our improved third quarter performance was driven by organic growth from our Academia & Government and Life Sciences & Healthcare (LS&H) segments, each delivering their highest quarterly revenue growth rate over the past year,” said Jonathan Gear, Chief Executive Officer. “During the quarter, we secured new customer wins across all three of our segments and launched new product offerings including an AI-powered tool to simplify IP budgets and forecasts and an enhanced search platform within LS&H powered by generative artificial intelligence. We continue to drive operational improvements and innovation, which will benefit both our customers and Clarivate in the future.”

1

Selected Financial Information

The prior year results include MarkMonitor, which was divested on October 31, 2022, for which there are no comparable amounts in the current year periods.

Three Months Ended September 30,ChangeNine Months Ended September 30,Change

(in millions, except percentages and per share data), (unaudited)20232022 $%20232022$%

Revenues, net$647.2 $635.7 $11.5 1.8 %$1,945.1 $1,984.5 $(39.4)(2.0)%

Net loss attributable to ordinary shares$(6.6)$(4,434.4)$4,427.8 N/M$(123.6)$(4,339.9)$4,216.3 N/M

Net loss per share, diluted$(0.01)$(6.64)$6.63 N/M$(0.18)$(6.66)$6.48 N/M

Weighted-average ordinary shares (diluted)670.9 675.2 — (0.6)%673.9 680.6 — (1.0)%

Adjusted EBITDA(1) $281.4 $271.6 $9.8 3.6 %$819.0 $808.3 $10.7 1.3 %

Adjusted net income(1) $152.6 $143.7 $8.9 6.2 %$435.7 $464.0 $(28.3)(6.1)%

Adjusted diluted EPS(1)(3) $0.21 $0.20 $0.01 5.0 %$0.59 $0.63 $(0.04)(6.3)%

Adjusted weighted-average ordinary shares (diluted)(1)

731.4 732.9 — (0.2)%733.6 739.0 — (0.7)%

Net cash provided by operating activities$163.4 $207.8 $(44.4)(21.3)%$553.3 $372.4 $180.9 48.6 %

Free cash flow(1) $101.7 $140.4 $(38.7)(27.5)%$374.7 $215.9 $158.8 73.6 %

Third Quarter 2023 Commentary

Subscription revenues for the third quarter decreased $0.2 million, or 0.0%, to $408.1 million, and decreased 3.2% on a constant currency basis(2), due to the divestiture of MarkMonitor. Organic subscription revenues increased 1.3%, primarily due to price increases and the benefit of net installations.

Re-occurring revenues for the third quarter increased $4.1 million, or 4.0% to $106.8 million, and increased 0.5% on a constant currency basis(2). Organic re-occurring revenues increased 0.5%, due to increased patent renewal volumes.

Transactional and other revenues for the third quarter increased $7.3 million, or 5.8%, to $132.3 million, and increased 3.1% on a constant currency basis(2). Organic transactional and other revenues increased 3.5%, due to higher transactional sales in the Academia & Government and

EX-99.1

2 ex991q12022earningsrelease.htm

EX-99.1

Document

Clarivate Reports First Quarter 2022 Results

— Reaffirms 2022 Outlook —

London, UK -- May 9, 2022 - Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in providing trusted information and insights to accelerate the pace of innovation, today reported results for the first quarter ended March 31, 2022.

First Quarter 2022 Financial Highlights

•Revenues of $662.2 million increased 54.6%, and 57.6% at constant currency

•Organic revenues(1) increased 4.4% at constant currency

•Net income(2) attributable to ordinary shares of $50.8 million increased $106.8 million; Net loss per diluted share of $0.06 improved by $0.11

•Adjusted Net Income(1) of $155.1 million increased 75.4%; Adjusted Income per diluted share(1) of $0.21 increased 50.0% or $0.07

•Adjusted EBITDA(1) of $262.3 million increased 59.2% and Adjusted EBITDA Margin(1) of 39.6% increased 140 basis points

“Clarivate had a good start to the year with organic revenue growth of 4.4% and strong profit conversion,” said Jerre Stead, Executive Chair and CEO. “The recent implementation of our 'One Clarivate' operating model is showing early signs of success as we delivered some cross-selling wins in the quarter. We also benefited by closing on several transactional deals, which had slipped from last year's fourth quarter.”

Selected Financial Information

The results for the three months ended March 31, 2022 include contributions from the following 2021 acquisitions 1) Bioinfogate, which was completed in August 2021; and 2) ProQuest, which was completed in December 2021 for which there were no comparable amounts in the three months ended March 31, 2021.

1

Three Months Ended March 31,Change

(in millions, except percentages and per share data), (unaudited)20222021 $%

Revenues, net$662.2 $428.4 $233.8 54.6 %

Annualized Contract Value (ACV)$1,606.5  $909.4 $697.1 76.7 %

Net income (loss) attributable to ordinary shareholders$50.8 $(56.0)$106.8 190.7 %

Net income (loss) per share, basic$0.07 $(0.09)$0.16 177.8 %

Net income (loss) per share, diluted$(0.06)$(0.17)$0.11 64.7 %

Weighted-average shares outstanding (diluted)688.0 612.6 — 12.3 %

Adjusted EBITDA(1) $262.3 $164.8 $97.5 59.2 %

Adjusted net income(1) $155.1 $88.4 $66.7 75.4 %

Adjusted diluted EPS(1) $0.21 $0.14 $0.07 50.0 %

Weighted average ordinary shares (diluted)(2) 746.3 623.3 — 19.7 %

Net cash provided by operating activities$67.4 $174.0 $(106.6)(61.3)%

Free cash flow(1) $26.0 $141.0 $(115.0)(81.6)%

Adjusted free cash flow(1) $191.3 $163.2 $28.1 17.2 %

(Amounts in tables may not sum due to rounding)

(1) Non-GAAP measure. Please see “Reconciliation to Certain Non-GAAP measures” in this earnings release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings release.

(2) Calculated assuming a net income position compared to a net loss position on the statement of operations for calculating Adjusted net income and Adjusted diluted EPS.

First Quarter 2022 Operating Results

Revenues, net, for the first quarter increased $233.8 million, or 54.6%, to $662.2 million, and increased 57.6% on a constant currency basis. Organic revenues(1) increased $18.7 million or 4.4% on a constant currency basis.

Subscription revenues for the first quarter increased $164.8 million, or 69.0%, to $403.8 million, and increased 71.5% on a constant currency basis, primarily driven by the acquisition of ProQuest in December 2021. Organic subscription revenues(1) increased 2.8% on a constant currency basis, primarily due to price increases, new business and the benefit of net installations in the prior year.

Re-occurring revenues for the first quarter increased $5.0 million, or 4.6% to $114.5 million, and increased 9.3% on a constant currency basis. Organic re-occurring revenues(1) increased 9.3% on a constant currency basis, primarily due to price increases in patent renewal volumes and improvement in yield per case.

Transactional revenues for the first quarter increased $60.8 million, or 73.3%, to $143.7 million, and increased 75.6% on a constant currency basis, primarily due to the acquisition of ProQuest. Organic transactional revenues(1) increased 2.3% on a constant currency basis, primarily due to an increase in custom data sales.

Net income attributable to ordinary shares for the first quarter improved to $50.8 million, compared to Net loss of $56.0 million in the prior-year period, primarily driven by the mark-to-market gain on financial instruments, higher revenues and profits. Net loss per diluted share for the first quarter of $(0.06) improved $0.11, compared to Net loss per diluted share of $(0.17) in the prior-year period.

Adjusted EBITDA for the first quarter was $262.3 million, an increase of $97.5 million or 59.2%. Adjusted net income for the first quarter was $155.1 million, an increase of $6

EX-99.1

2 ex991q42021earningsrelease.htm

EX-99.1

Document

Clarivate Reports Fourth Quarter and Full Year 2021 Results

— Reaffirms outlook for 2022 —

London, UK -- March 10, 2022 - Clarivate Plc (NYSE: CLVT) (the “Company” or “Clarivate”), a global leader in providing trusted information and insights to accelerate the pace of innovation, today reported results for the fourth quarter and year ended December 31, 2021.

Fourth Quarter 2021 Financial Highlights

•Revenues of $560.7 million increased 23.1%, and 24.3% at constant currency

•Adjusted Revenues(1) of $560.2 million increased 18.9%, and 20.1% at constant currency

•Adjusted organic revenues(1) increased 4.0% at constant currency

•Net loss(2) attributable to ordinary shares of $130.4 million increased $116.7 million; Net loss per diluted share of $0.20 increased $0.15

•Adjusted Net Income(1) of $163.2 million increased 20.4%; Adjusted Income per diluted share(1) of $0.23 increased 4.7% or $0.01

•Adjusted EBITDA(1) of $256.6 million increased 28.3% and Adjusted EBITDA Margin(1) of 45.8% increased 340 basis points

Full Year 2021 Financial Highlights

•Revenues of $1,876.9 million increased 49.7%, and 48.3% at constant currency

•Adjusted Revenues(1) of $1,880.8 million increased 47.3%, and 46.0% at constant currency

•Adjusted organic revenues(1) increased 4.5% at constant currency

•Net loss(2) attributable to ordinary shares of $312.0 million improved $38.7 million; Net loss per diluted share of $0.61 improved $0.21

•Adjusted Net Income(1) of $481.7 million increased 66.6%; Adjusted Income per diluted share(1) of $0.72 increased 11.5% or $0.08

•Adjusted EBITDA(1) of $800.4 million increased 64.5% and Adjusted EBITDA Margin(1) of 42.6% increased 450 basis points

•Cash Flow from Operations increased $60.3 million to $323.8 million; Adjusted Free Cash Flow(1) increased $157.8 million to $459.4 million

Jerre Stead, Executive Chair and CEO, said: “We delivered good subscription and re-occurring revenue growth and grew our Adjusted EBITDA margin in the fourth quarter. Transactional revenues faced some headwinds late in the quarter, which prevented us from delivering better results. However, we are taking steps to improve this smaller segment of our business.”

“2021 continued to be a transformative year for us. We enhanced our academic offerings with the acquisition of ProQuest, completed the inside sales customer migration to better serve more than 24,000 customers, launched more than 90 new product offerings and enhancements, and continued to deliver on cost savings initiatives. With our One Clarivate vision, which aligns our operations into four customer verticals to focus outside-in on

1 Represents a Non-GAAP measure. Please see “Reconciliation to Certain Non-GAAP measures” in this earnings release for important disclosures and reconciliations of these financial measures to the most directly comparable GAAP measure. These terms are defined elsewhere in this earnings press release.

2 Net loss margin change from comparable period is not meaningful.

1

our customers and the complete portfolio of solutions we can offer them, we are poised to deliver improved growth and exceptional cash flows in 2022.”

Selected Financial Information

The results for the year ended December 31, 2021 include contributions from the following 2020 acquisitions: 1) CPA Global, which was completed in October 2020; 2) Beijing Incopat Co., Ltd ("IncoPat"), which was completed in October 2020; 3) Hanlim IPS Co., Ltd ("Hanlim"), which was completed in November 2020; and 4) DRG, which was completed in February 2020. Additionally, the results for the year ended December 31, 2021 include contributions from the following 2021 acquisitions: 1) Bioinfogate, which was completed in August 2021; and 2) ProQuest, which was completed in December 2021 for which there were no comparable amounts in the year ended December 31, 2020. The results for the three months and year ended December 31, 2021 exclude the results of Techstreet, which was divested in November 2020.

Three Months Ended December 31,ChangeYear Ended December 31, Change

(in millions, except percentages and per share data); (unaudited) 20212020 $%20212020$%

Revenues, net$560.7 $455.6 $105.1 23.1 %$1,876.9 $1,254.0 $622.8 49.7 %

Adjusted revenues, net(1) $560.2 $471.3 $88.9 18.9 %$1,880.8 $1,277.1 $603.7 47.3 %

Annualized Contract Value (ACV)$1,611.8  $906.6$705.2 77.8 %$1,611.8 $906.6$705.2 77.8 %

Net loss attributable to ordinary shareholders$(130.4)$(13.7)$116.7 850.3 %$(312.0)$(350.6)$(38.7)(11.0)%

Net loss per share$(0.20)$(0.02)$0.18 770.3 %$(0.49)$(0.82)$(0.33)(39.8)%

Weighted-average shares outstanding (diluted)654.9 610.6 — 7.3 %640.8 427.0 — 50.1 %

Adjusted EBITDA(1) $256.6 $200.1 $56.5 28.3 %$800.4 $486.6 $313.8 64.5 %

Adjusted net income(1) $163.2 $135.6 $27.6 20.4 %$481.7 $289.1 $192.5 66.6 %

Adjusted diluted EPS(1) $0.23 $0.22 $0.01 4.7 %$0.72 $0.64 $0.08 11.5 %

Weighted average ordinary shares